A fully human IgG1κ monoclonal antibody that binds the conserved AD-2 site I epitope on HCMV glycoprotein B (gB), neutralizing virus by blocking gB-mediated attachment/fusion and cell-to-cell spread, and engaging Fc-mediated effector functions (ADCC and complement).
Fully human IgG1κ monoclonal antibody that binds the conserved AD‑2 site I epitope on HCMV glycoprotein B (gB), neutralizing virus by blocking gB‑mediated attachment/fusion and cell‑to‑cell spread, while engaging Fc‑mediated effector functions (ADCC and complement) to enhance clearance.
NO
INDIRECT
The antibody binds HCMV gB on infected cells and recruits Fc-mediated ADCC and complement (C1q) to lyse those infected cells. C1q (C1q C chain) is only a recruited complement component, not the antigen; cells expressing C1q are not directly targeted or killed.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
YES
DIRECT
The Y-90–labeled anti-CD66 antibody binds CEACAM8 (CD66b) on granulocytic cells and emits beta radiation that causes DNA double-strand breaks and lethal damage, directly ablating the bound target cells (with some local crossfire effect).
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
YES
DIRECT
The 90Y-labeled anti-CD66 antibody binds CD66/CEACAM antigens on myeloid cells; bound radionuclide emits beta radiation that causes DNA double-strand breaks and cell death in antigen-expressing cells (with some crossfire to nearby cells).
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
YES
DIRECT
The Y-90–labeled anti-CD66 (BW250/183) antibody binds CEACAM6 (CD66c) on target cells and delivers beta radiation that induces DNA damage (double‑strand breaks) leading to cell death.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
YES
DIRECT
The anti-CD66 (CEACAM) antibody BW250/183 binds CEACAM1 (CD66a) and delivers Yttrium-90 beta radiation to the bound cells, causing DNA damage (double-strand breaks) and cell death, with some crossfire to nearby cells.